4DMedical Ltd ( (AU:4DX) ) has shared an update.
4DMedical Limited has successfully raised $5.5 million through the issuance of 12,941,176 new shares to institutional and professional investors at $0.425 per share. This capital raise, conducted under the company’s existing placement capacity, is expected to bolster 4DMedical’s financial position and support its ongoing innovations in respiratory care technology, potentially enhancing its market presence and stakeholder value.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced imaging and AI-powered solutions for respiratory care. The company’s patented XV Technology® provides detailed insights into lung function, supporting early and precise diagnosis of respiratory diseases. Their solutions, including the FDA-cleared XV Lung Ventilation Analysis Software, integrate with existing hospital systems via a SaaS model. In 2023, 4DMedical expanded its capabilities by acquiring Imbio, enhancing its AI-driven platforms for chronic lung and cardiothoracic diseases.
YTD Price Performance: -13.54%
Average Trading Volume: 936,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$171.9M
For a thorough assessment of 4DX stock, go to TipRanks’ Stock Analysis page.